Vol. 13. Núm. 36.
Páginas 2107-2112 (Junio 2021)

Protocolos de práctica asistencial
Protocolo de objetivos terapéuticos en pacientes con riesgo cardiovascular. Diabetes y dislipemia

Protocol of therapeutic objectives in patients with cardiovascular risk. Diabetes and dyslipidaemia

A. Lorente RosE.A. Rajjoub Al-MahdiR.R. Martínez MoyaJ.L. Zamorano Gómez
Doi : https://10.1016/j.med.2021.06.016
Opciones
Resumen

El control de los factores de riesgo cardiovascular es clave en la prevención de la morbimortalidad asociada a la enfermedad cardiovascular: es la estrategia más eficaz a nivel poblacional, y ha demostrado ser coste-efectiva en una gran variedad de escenarios. Según las guías actuales, los objetivos terapéuticos recomendados para cada individuo dependen de la evaluación de su riesgo cardiovascular total y del tipo de prevención. En vista de la evidencia acumulada en los últimos años, se han adoptado objetivos más estrictos en el control de los factores de riesgo cardiovascular, especialmente en sujetos de alto riesgo y en prevención secundaria. En este protocolo revisaremos los principales objetivos terapéuticos de los pacientes con diabetes y dislipemia en función de su riesgo cardiovascular.

Palabras clave
Objetivos terapéuticos
LDL
Enfermedad cardiovascular
Colesterol
Diabetes
Abstract

Control of cardiovascular risk factors is crucial in the prevention of morbidity and mortality associated with cardiovascular disease. It is the most effective strategy at the population level, and has been shown to be cost-effective in a wide variety of settings. According to current guidelines, the recommended therapeutic targets for each individual depend on the assessment of their total cardiovascular risk and type of prevention. From the evidence accumulated in recent years, stricter targets for cardiovascular risk factor control have been adopted, especially in high-risk subjects and in secondary prevention. In this protocol we shall review the main therapeutic targets for patients with diabetes and dyslipidaemia according to their cardiovascular risk.

Keywords
Therapeutic targets
LDL
Cardiovascular disease
Cholesterol
Diabetes

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
F. Cosentino
202106251132324778
202106251132324779
, P.J. Grant, V. Aboyans, C.J. Bailey, A. Ceriello, V. Delgado, et al.
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Eur Heart J., (2020), 41 pp. 255-323
[2]
F. Mach
2021062511323247710
2021062511323247711
, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, et al.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Eur Heart J., (2020), 41 pp. 111-188
[3]
M.F. Piepoli
2021062511323247712
2021062511323247713
, A.W. Hoes, S. Agewall, C. Albus, C. Brotons, A.L. Catapano, et al.
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
Eur Heart J., (2016), 37 pp. 2315-2381
[4]
T.J. Moore
2021062511323247714
, W.M. Vollmer, L.J. Appel, F.M. Sacks, L.P. Svetkey, T.M. Vogt, et al.
Effect of dietary patterns on ambulatory blood pressure: results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group.
Hypertension., (1999), 34 pp. 472-477
[5]
M.A. Martínez-González
2021062511323247715
, J. Salas-Salvadó, R. Estruch, D. Corella, M. Fitó, E. Ros, et al.
Benefits of the Mediterranean Diet: Insights From the PREDIMED Study.
Prog Cardiovasc Dis., (2015), 58 pp. 50-60
[6]
D.E. Threapleton
2021062511323247716
, D.C. Greenwood, C.E.L. Evans, C.L. Cleghorn, C. Nykjaer, C. Woodhead, et al.
Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis.
BMJ., (2013), 347 pp. f6879
[7]
E.D. Parker
2021062511323247717
, L.J. Harnack, A.R. Folsom.
Nut consumption and risk of type 2 diabetes.
JAMA., (2003), 290 pp. 38-39
[8]
S. Bangalore
2021062511323247718
2021062511323247719
, S. Kumar, I. Lobach, F.H. Messerli.
Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.
Circulation., (2011), 123 pp. 2799-2810
[9]
N. Laiteerapong
2021062511323247720
2021062511323247721
, S.A. Ham, Y. Gao, H.H. Moffet, J.Y. Liu, E.S. Huang, et al.
The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study).
Diabetes Care., (2019), 42 pp. 416-426